99mTc-焦磷酸盐SPECT/CT中心脏与纵隔比值对转甲状腺素蛋白心脏淀粉样变性的诊断价值
该研究回顾性纳入2019年3月至2022年1月间接受99mTc-焦磷酸盐SPECT/CT的164例患者,经心内膜心肌活检筛选后30例(转甲状腺素蛋白心脏淀粉样变性15例、非转甲状腺素蛋白心脏淀粉样变性15例)纳入分析,评估给药后3小时心脏与纵隔比值(H/M)和心脏与对侧肺比值(H/CL)的诊断准确性。H/M比值>1.41诊断转甲状腺素蛋白心脏淀粉样变性的灵敏度、特异度、阳性预测值和阴性预测值分别为100%、93.3%、93.3%和100%,H/CL比值>1.3分别为100%、40.0%、62.5%和100%。
要点
- 给药后3小时H/M比值>1.41诊断转甲状腺素蛋白心脏淀粉样变性灵敏度100%、特异度93.3%。
- H/CL比值>1.3诊断转甲状腺素蛋白心脏淀粉样变性特异度仅40.0%、阳性预测值62.5%。
- H/M比值受血液放射性滞留影响较小,可能为转甲状腺素蛋白心脏淀粉样变性提供新的诊断指标。
核心结论
- 给药后3小时计算的H/M比值有潜力成为诊断转甲状腺素蛋白心脏淀粉样变性的新指标。
研究设计与样本
- 回顾性纳入2019年3月至2022年1月间接受99mTc-焦磷酸盐SPECT/CT的164例患者。
- 排除未行心内膜心肌活检者后,30例患者纳入分析,其中转甲状腺素蛋白心脏淀粉样变性15例、非转甲状腺素蛋白心脏淀粉样变性15例。
- 在给药后3小时计算H/M比值和H/CL比值,并评估其对转甲状腺素蛋白心脏淀粉样变性的诊断准确性。
主要发现
- 受试者工作特征曲线区分转甲状腺素蛋白心脏淀粉样变性与非转甲状腺素蛋白心脏淀粉样变性患者的曲线下面积分别为0.986和0.943。
- H/M比值>1.41诊断转甲状腺素蛋白心脏淀粉样变性的灵敏度100%、特异度93.3%、阳性预测值93.3%、阴性预测值100%。
- H/CL比值>1.3诊断转甲状腺素蛋白心脏淀粉样变性的灵敏度100%、特异度40.0%、阳性预测值62.5%、阴性预测值100%。
关键数值与推荐
- H/M比值>1.41:灵敏度100%、特异度93.3%、阳性预测值93.3%、阴性预测值100%。
- H/CL比值>1.3:灵敏度100%、特异度40.0%、阳性预测值62.5%、阴性预测值100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In transthyretin cardiac amyloidosis (ATTR-CA), 99mTc-pyrophosphate myocardial scintigraphy (99mTc-PYP) is a diagnostic tool that utilizes visual and quantitative evaluation. However, false positive cases can occur because of tracer accumulation in the blood. We investigated the effectiveness of the heart-to-mediastinum (H/M) ratio of 99mTc-PYP in ATTR-CA diagnosis. METHODS: We retrospectively included 164 patients who underwent 99mTc-PYP single-photon emission computed tomography/computed tomography between March 2019 and January 2022. The diagnostic accuracy of ATTR-CA was examined by the heart-to-contralateral lung (H/CL) and H/M ratio calculated at 3 hours post-tracer administration. RESULTS: After the exclusion of patients who did not undergo endomyocardial biopsy, 30 patients (15 each with ATTR-CA and without ATTR-CA) were included. The receiver operating characteristic curve used to distinguish ATTR-CA from non-ATTR-CA patients revealed an area under the curve of 0.986 and 0.943, respectively. A H/M ratio of > 1.41 identified ATTR-CA patients with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 93.3, 93.3, and 100%, respectively. Conversely, an H/CL ratio of > 1.3 identified ATTR-CA patients with 100% sensitivity, 40.0% specificity, 62.5% PPV, and 100% NPV. CONCLUSION: The H/M ratio obtained at 3 hours post-injection has the potential to be a novel indicator for ATTR-CA.
引用
- Ikoma T, Ohtani H, Ohno K, et al. Diagnostic value of heart-to-mediastinum ratio in 99mTc-pyrophospate SPECT/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2022. PMID: 36547805. doi:10.1007/s12350-022-03180-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。